<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31664949</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>A retrospective study of the clinical phenotype and predictors of survival in non-Caucasian Hispanic patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>261</StartPage><MedlinePgn>261</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">261</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-019-1459-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known about the clinical phenotype of amyotrophic lateral sclerosis (ALS) in non-Caucasian populations. Here, we aimed to describe the clinical characteristics, prognostic factors and survival of Mexican patients with ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study by reviewing the medical records of patients with ALS that attended and were regularly followed at a third level hospital in Mexico City from 2000 to 2015. We calculated absolute and relative frequencies of the clinical characteristics from all the participants. We also estimated correlation coefficients between clinical features and overall survival. Additionally, survival rates were compared for all participants grouped according to different clinical features using the Kaplan-Meier method and the log-rank test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We enrolled 45 ALS patients, 53.33% had spinal-onset ALS and 46.66% presented bulbar ALS. The male/female ratio was 0.8. The mean age at onset of symptoms was 58.11&#x2009;years. Mean survival time from onset was 64.73&#x2009;&#xb1;&#x2009;34.83&#x2009;months. Cumulative survival rate after 5&#x2009;years of disease onset was 44.44%. Age at onset and age at diagnosis inversely correlated with overall survival time. Also, we found that bulbar-onset, short diagnostic delay, percutaneous endoscopic gastrostomy, mechanical ventilation, and lower total cholesterol serum levels were associated with short survival.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The clinical characteristics of Mexican ALS patients differ from the disease phenotype observed in Caucasians. Nonetheless, the predictive value of certain well-recognized prognostic factors remains consistent in our population. The current study provides relevant information for a better understanding of prognostic factors in ALS patients from Mexico and other Latin American countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xe1;nchez-Mart&#xed;nez</LastName><ForeName>Claudia Marisol</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Centro M&#xe9;dico Nacional 20 de Noviembre, ISSSTE, F&#xe9;lix Cuevas, 540, Col del Valle Sur, 03100, Mexico City, Mexico. clamar789@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chore&#xf1;o-Parra</LastName><ForeName>Jos&#xe9; Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Research, Centro Especializado en Neurocirug&#xed;a y Neurociencias M&#xe9;xico (CENNM), Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Escuela Nacional de Ciencias Biol&#xf3;gicas, Instituto Polit&#xe9;cnico Nacional, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nu&#xf1;ez-Orozco</LastName><ForeName>Lilia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Centro M&#xe9;dico Nacional 20 de Noviembre, ISSSTE, F&#xe9;lix Cuevas, 540, Col del Valle Sur, 03100, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Placencia-&#xc1;lvarez</LastName><ForeName>Noel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Centro M&#xe9;dico Nacional 20 de Noviembre, ISSSTE, F&#xe9;lix Cuevas, 540, Col del Valle Sur, 03100, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvis-Casta&#xf1;o</LastName><ForeName>Laura Marcela</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Centro M&#xe9;dico Nacional 20 de Noviembre, ISSSTE, F&#xe9;lix Cuevas, 540, Col del Valle Sur, 03100, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guadarrama-Ortiz</LastName><ForeName>Parm&#xe9;nides</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5672-2414</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Centro Especializado en Neurocirug&#xed;a y Neurociencias M&#xe9;xico (CENNM), Tlaxcala &amp; Manzanillo, Roma Sur, 06760, Mexico City, Mexico. investigacion.cientifica@cennm.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Bulbar-onset ALS</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Prognostic factors</Keyword><Keyword MajorTopicYN="N">Spinal-onset ALS</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31664949</ArticleId><ArticleId IdType="pmc">PMC6819359</ArticleId><ArticleId IdType="doi">10.1186/s12883-019-1459-3</ArticleId><ArticleId IdType="pii">10.1186/s12883-019-1459-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile F, Scarlino S, Falzone YM, Lunetta C, Tremolizzo L, Quattrini A, et al. The peripheral nervous system in amyotrophic lateral sclerosis: opportunities for translational research. Front Neurosci. 2019;13:601. doi: 10.3389/fnins.2019.00601.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00601</ArticleId><ArticleId IdType="pmc">PMC6603245</ArticleId><ArticleId IdType="pubmed">31293369</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Chen KS, Paez-Colasante X, Feldman EL. Emerging understanding of the genotype&#x2013;phenotype relationship in amyotrophic lateral sclerosis. Handb Clin Neurol. 2018;148:603&#x2013;623. doi: 10.1016/B978-0-444-64076-5.00039-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-64076-5.00039-9</ArticleId><ArticleId IdType="pubmed">29478603</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Logroscino G, Boum&#xe9;diene F, Labrunie A, Couratier P, Babron MC, et al. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur J Epidemiol. 2016;31(3):229&#x2013;245. doi: 10.1007/s10654-015-0090-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0090-x</ArticleId><ArticleId IdType="pubmed">26458931</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68(13):1002&#x2013;1007. doi: 10.1212/01.wnl.0000258551.96893.6f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000258551.96893.6f</ArticleId><ArticleId IdType="pubmed">17389304</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9; diene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, et al. Variation in world wide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46(1):57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis symbol. Neurology. 2008;70(13):1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, K&#xfc;hnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez MC, Ketzoi&#xe1;n C, Legnani C, Rega I, S&#xe1;nchez N, Perna A, et al. Incidence and prevalence of amyotrophic lateral sclerosis in Uruguay: a population-based study. Neuroepidemiology. 2008;30(2):105&#x2013;111. doi: 10.1159/000120023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000120023</ArticleId><ArticleId IdType="pubmed">18334826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology. 2009;72(19):1640&#x2013;1645. doi: 10.1212/WNL.0b013e3181a55f7b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a55f7b</ArticleId><ArticleId IdType="pubmed">19433736</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez HR, Molina-L&#xf3;pez JF, Cant&#xfa;-Mart&#xed;nez L, Gonz&#xe1;lez-Garza MT, Moreno-Cuevas JE, Couret-Alcaraz P, et al. Survival and clinical features in Hispanic amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler. 2011;12(3):199&#x2013;205. doi: 10.3109/17482968.2010.550302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.550302</ArticleId><ArticleId IdType="pubmed">21344998</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes RB, Colville S, Parratt J, Swingler RJ. The incidence of motor nueron disease in Scotland. J Neurol. 2007;254(7):866&#x2013;869. doi: 10.1007/s00415-006-0454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0454-y</ArticleId><ArticleId IdType="pubmed">17420925</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsgren L, Almay BGL, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand. 1983;68(1):20&#x2013;29. doi: 10.1111/j.1600-0404.1983.tb04810.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1983.tb04810.x</ArticleId><ArticleId IdType="pubmed">6604389</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry. 2008;79(1):30&#x2013;32. doi: 10.1136/jnnp.2007.117788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.117788</ArticleId><ArticleId IdType="pubmed">17634215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Moglia C, Manera U, Canosa A, Cammarosano S, et al. Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d&#x2019;Aosta register. JAMA Neurol. 2017;74(9):1097&#x2013;1104. doi: 10.1001/jamaneurol.2017.1387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1387</ArticleId><ArticleId IdType="pmc">PMC5710181</ArticleId><ArticleId IdType="pubmed">28692730</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Front Degener. 2015;16(3&#x2013;4):230&#x2013;236. doi: 10.3109/21678421.2014.990036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.990036</ArticleId><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil C, Zach N, Rishoni S, Shalev V, Chodick G. Epidemiology of amyotrophic lateral sclerosis: a population-based study in Israel. Neuroepidemiology. 2016;47(2):76&#x2013;81. doi: 10.1159/000448921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000448921</ArticleId><ArticleId IdType="pubmed">27617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006;253(11):1428&#x2013;1436. doi: 10.1007/s00415-006-0226-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0226-8</ArticleId><ArticleId IdType="pubmed">16773270</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura MC, Novaes MRCG, Eduardo EJ, Zago YSSP. Del negro Barroso Freitas R, Casulari LA. Prognostic factors in amyotrophic lateral sclerosis: a population-based study. PLoS One. 2015;10(10):e0141500. doi: 10.1371/journal.pone.0141500..</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141500.</ArticleId><ArticleId IdType="pmc">PMC4627754</ArticleId><ArticleId IdType="pubmed">26517122</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol. 2000;57(1):109&#x2013;113. doi: 10.1001/archneur.57.1.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.1.109</ArticleId><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabkin J, Ogino M, Goetz R, Mcelhiney M, Hupf J, Heitzman D, et al. Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey. Amyotroph Lateral Scler Front Degener. 2014;15(3&#x2013;4):185&#x2013;191. doi: 10.3109/21678421.2014.896928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.896928</ArticleId><ArticleId IdType="pubmed">24720451</ArticleId></ArticleIdList></Reference><Reference><Citation>del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813&#x2013;819. doi: 10.1212/01.WNL.0000049472.47709.3B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000049472.47709.3B</ArticleId><ArticleId IdType="pubmed">12629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D&#x2019;Ovidio F, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;90(6):666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF treatment study group. Neurology. 1998;50(1):66&#x2013;72. doi: 10.1212/WNL.50.1.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.50.1.66</ArticleId><ArticleId IdType="pubmed">9443459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, Mcdermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7&#x2013;8):478&#x2013;484. doi: 10.3109/21678421.2015.1062517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062517</ArticleId><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufr&#xe8;re B, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74(3):328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390&#x2013;392. doi: 10.1136/jnnp.2005.072660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong ML, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS One. 2017;12(4):e0174925. doi: 10.1371/journal.pone.0174925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>